Hemophagocytic lymphohistiocytosis associated with sodium valproate

Authors

  • Xiang-Dong Zeng Chengdu Women’s and Children’s Central Hospital
  • Ping Liu Chengdu Women’s and Children’s Central Hospital
  • Wen-Guang Hu Chengdu Women’s and Children’s Central Hospital

DOI:

https://doi.org/10.54029/2023rzw

Keywords:

epilepsy, hemophagocytic lymphohistiocytosis, valproate

Abstract

Hemophagocytic lymphohistiocytosis(HLH) is known to have numerous causes, such as chronic inflammation, infection, malignancy, drug use, and primary or familial HLH. HLH triggered by valproate (VPA) has rarely been reported in the literature. Here we describe a pediatric patient with HLH induced by VPA. A 5-years-old girl presented to our center with recurrent fever accompanied by diffuse generalized rash after 2 weeks of taking oral VPA. Physical examination revealed hepatosplenomegaly; laboratory findings showed bicytopenia (hemoglobin and platelet), hemophagocytic cells on the bone marrow smear, hypofibrinogenaemia and hypertriglyceridaemia, and a high ferritin level. She was diagnosed to have HLH associated with VPA. She was treated with intravenous immunoglobulin, glucocorticoid and withdrawal of the sodium valproate, and she completely recovered. In conclusion, VPA can trigger HLH, a potentially fatal condition.

Published

2023-09-30

Issue

Section

Case Report